4.6 Review

Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma

Journal

GENES
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/genes12101500

Keywords

rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; fusion-negative RMS; fusion-positive RMS

Ask authors/readers for more resources

Rhabdomyosarcoma is the most common soft tissue sarcoma in children and adolescents, but the prognosis has not significantly improved in recent years. Researchers are working to better understand the genetic abnormalities and risk stratification of the disease in order to develop more effective therapeutic strategies.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents and accounts for approximately 2% of soft tissue sarcomas in adults. It is subcategorized into distinct subtypes based on histological features and fusion status (PAX-FOXO1/VGLL2/NCOA2). Despite advances in our understanding of the pathobiological and molecular landscape of RMS, the prognosis of these tumors has not significantly improved in recent years. Developing a better understanding of genetic abnormalities and risk stratification beyond the fusion status are crucial to developing better therapeutic strategies. Herein, we aim to highlight the genetic pathways/abnormalities involved, specifically in fusion-negative RMS, assess the currently available model systems to study RMS pathogenesis, and discuss available prognostic factors as well as their importance for risk stratification to achieve optimal therapeutic management.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available